Aspirin for everyone older than 50?
Authors:
Abstract
Introduction It is 30 years since the first randomised trial was published showing a link between aspirin and myocardial infarction.1 We believe that the evidence now supports more widespread use of aspirin prophylaxis, and there needs to be a strategy to inform the public and enable older people to make their own decision. The evidence focuses on a crucial question—namely, at what age does the balance between benefit and risk justify low dose aspirin prophylaxis? Of further relevance is a possible reduction of cancer and dementia by aspirin.Keywords
This publication has 14 references indexed in Scilit:
- Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic ReviewNeuroepidemiology, 2004
- Evidence for colorectal cancer cell specificity of aspirin effects on NFκB signalling and apoptosisBritish Journal of Cancer, 2004
- Mendelian randomization: prospects, potentials, and limitationsInternational Journal of Epidemiology, 2004
- A strategy to reduce cardiovascular disease by more than 80%BMJ, 2003
- Adverse Drug Events in Ambulatory CareNew England Journal of Medicine, 2003
- Epidemiology of Non-Steroidal Anti-Inflammatory Drugs and Cancer2003
- Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart diseaseBMJ, 1997
- Cardiovascular disease risk profilesAmerican Heart Journal, 1991
- Caerphilly and Speedwell collaborative heart disease studies. The Caerphilly and Speedwell Collaborative Group.Journal of Epidemiology and Community Health, 1984
- A Randomized Controlled Trial of Acetyl Salicyclic Acid in the Secondary Prevention of Mortality from Myocardial InfarctionBMJ, 1974